Polymerase News and Research

RSS

Presence of neoehrlichiosis confirmed in Switzerland

Researchers have confirmed the presence of a novel tick-borne disease known as neoehrlichiosis in Switzerland.

8 Nov 2012

Phase II study to evaluate Medivir/Janssen's simeprevir and Vertex against HCV

Medivir AB, announced today plans for a phase II proof-of-concept study of an all-oral regimen for the treatment of hepatitis C containing of Medivir/Janssen's protease inhibitor simeprevir and Vertex's nucleotide analogue hepatitis C virus (HCV) polymerase inhibitor VX-135.

3 Nov 2012

Janssen, Vertex to evaluate TMC435 and VX-135 in Phase 2 HCV study

Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

2 Nov 2012

Bacterial pathogen ‘acutely’ involved in otitis media

Alloiococcus otitidis can be a dominant bacterial pathogen among indigenous Australian children with acute otitis media with perforation, although its main role appears to be that of a secondary pathogen, preliminary study findings suggest.

10 Oct 2012

Study demonstrates efficacy of genotyping technology in identifying source of clinic infection outbreak

Researchers from East Carolina University used a new technique of genotyping to identify the source of a hematology clinic outbreak of Mycobacterium mucogenicum, a gram-positive, acid-fast bacteria found in tap water. This is the first outbreak of M. mucogenicum in an ambulatory care setting; five other outbreaks have been reported in hospital settings since 1995.

6 Oct 2012

Human hepatitis threat present in domestic pigs

The prevalence of hepatitis E virus in domestic pigs is between 10% and 30%, with a likelihood that infected pigs enter the pork production chain thereby threatening public health, indicate Portuguese study results.

2 Oct 2012

Pervenio Lung RS from Life Technologies

Life Technologies Corporation today announced the launch of Pervenio Lung RS. First-of-its-kind, the molecular test has been documented to reliably identify early stage lung cancer patients who are at high risk for mortality following surgery. It also fulfills an unmet need for prognostic information to guide preventative treatment and improve disease management.

25 Sep 2012

Medivir’s simeprevir and TMC647055 to enter phase IIa combination trial for HCV genotype-1

Medivir AB, announced today that simeprevir (TMC435) and TMC647055, a non-nucleoside inhibitor (NNI) will enter a phase IIa interferon free combination trial.

21 Sep 2012

Thermo Fisher Scientific announces opening of Molecular Biology Center of Excellence in Lithuania

Thermo Fisher Scientific Inc., the world leader in serving science, today announced the official opening of its Molecular Biology Center of Excellence in Vilnius, Lithuania.

From Thermo Fisher Scientific Inc. 20 Sep 2012

MRD monitoring falls short in childhood AML assessment

Measuring treatment response by minimal residual disease monitoring offers no more prognostic value than morphologic analysis in children with acute myeloid leukemia (AML), show study findings.

19 Sep 2012

Pertussis immunity wanes in the 5 years after DTaP vaccination

The risk for pertussis infection in children who receive the combined diphtheria, tetanus, and acellular pertussis vaccine increases by an average of 42% per year after the last dose, a US study shows.

17 Sep 2012

New test to assess viral load of cytomegalovirus

Roche announced today the commercial availability of a new test to assess a patient's viral load of cytomegalovirus (CMV). Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically patients with an immune system that has been suppressed for solid organ transplantation.

From Roche Sequencing and Life Science 17 Sep 2012

PARP inhibitors may be novel treatment strategy in women with HER2-positive breast cancers

Poly (ADP-Ribose) polymerase (PARP) inhibitors, shown to have clinical activity when used alone in women with familial breast and ovarian cancers linked to BRCA mutations, may be a novel treatment strategy in women with HER2-positive breast cancers, according to the results of a study published in Cancer Research, a journal of the American Association for Cancer Research.

17 Sep 2012

Flow cytometry renders PCR testing unnecessary for most AML patients

Early treatment response is a powerful predictor of long-term outcome for young patients with acute myeloid leukemia (AML). The information can help physicians decide whether a more intensive approach is needed. Research led by St. Jude Children's Research Hospital investigators has identified the best test for measuring that response and guiding therapy.

11 Sep 2012

Medivir strengthens hepatitis C platform

Medivir AB, announced today that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB. The acquisition includes intellectual property and prodrug technologies in order to further strengthen Medivir's hepatitis C platform and know how.

5 Sep 2012

DNA synthesis in the 3’ and 5’ direction possible using new template-directed method

When a cell divides, it passes on genetic information by producing copies of its DNA. Chemists have also learned to copy DNA. In the journal Angewandte Chemie, a German team has now introduced a new copying technique that uses a single strand of DNA as the “master copy”, like a cell, but does not require enzymes.

30 Aug 2012

Bristol-Myers Squibb terminates BMS-986094 Phase II development for treatment of hepatitis C

Bristol-Myers Squibb Company announced today that the Company has discontinued development of BMS-986094 (formerly known as INX-189), a nucleotide polymerase (NS5B) inhibitor that was in Phase II development for the treatment of hepatitis C.

24 Aug 2012

Live bacteria in more than 90% of middle ear effusions

Live bacteria are present in more than 90% of middle ear effusions, research shows.

20 Aug 2012

New England Biolabs releases Q5 High-Fidelity DNA Polymerase

New England Biolabs (NEB) has released a novel DNA polymerase, Q5 High-Fidelity DNA Polymerase, that provides the highest fidelity amplification currently available, while also offering robust amplification across the broadest range of amplicons, including those that are GC- and AT-rich.

From New England Biolabs 9 Aug 2012

Clovis Oncology reports net loss of $15.7 million for second quarter 2012

Clovis Oncology, Inc. today reported financial results for the second quarter 2012, and provided an update on the progress of its clinical development programs and expected milestones for the rest of the year.

8 Aug 2012